At The Medicine Shoppe® Pharmacies, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
Getting the Best Care for Lung Cancer
In the second of our series on lung cancer, we continue our conversation with one of the nation's experts on the subject. D. Ross Camidge , MD, PhD , is a well-known lung cancer specialist and director of the thoracic oncology clinical program at the University of Colorado.
Pfizer Drug Receives Positive Opinion for Lung Cancer
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU).
Resisting Cancer's Resistance
One of the many cruelties of cancer is that it may temporarily shrink in the presence of new drugs, only to come roaring back later.
Pfizer Announces Positive Results From Xalkori Trial
Pfizer Inc. announced today that the PROFILE 1007 study demonstrated that XALKORI ( crizotinib ) significantly improved progression-free survival ( PFS ) when compared with pemetrexed or docetaxel , in previously treated patients with anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer ( NSCLC ).
FDA Approves Xalkori and Vysis ALK Break Apart FISH Probe Kit
The U.S. Food and Drug Administration today approved Xalkori ( crizotinib ) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers ( NSCLC ) who express the abnormal anaplastic lymphoma kinase ( ALK ) gene.